Discoverpoint-of-care toolslike our insurance coverage checker for CGMs and medications and dosing info for T2D
Home
Admin PortalData Dashboard
RESOURCES ∨
NEWS
EVENTS
FOR MEMBERS ∨
VBR ∨
FOR PATIENTS
QUALITY INITIATIVES ∨
ABOUT ∨

MCT2D Clinician Decision Aid: SGLT-2 Inhibitor / GLP-1 RA for Type 2 Diabetes

Download Resource
Why this aid?
SGLT2-inhibitors and GLP-1 receptor agonists are two newer classes of medications for diabetes that reduce hyperglycemia, reduce endogenous insulin production, and improve cardiovascular and renal outcomes, weight loss, and mortality in Type 2 Diabetes.
This aid is meant to be used alongside your own clinical judgment and prescribing information to guide individualization of diabetes treatment.
Providers, have you used this tool? Give us your feedback to help improve it for others

Tags:

For ProvidersNon-videoPDFCreated-By-MCT2DPoint-of-care

Subscribe to the MCT2D Newsletter

* indicates required
Blue Cross Blue Shield Blue Care Network of Michigan

Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit www.valuepartnerships.com. Although Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes work in partnership, the opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

PATIENT STORIESPOINT-OF-CARE-TOOLSSUBMIT A CASE SUMMARYSUBMIT FEEDBACK